NCT00756912 is a Phase 1 clinical trial of E5564 in Leukemia, sponsored by Eisai Inc..

Who is sponsoring NCT00756912?

NCT00756912 is sponsored by Eisai Inc..

What drugs are being tested in NCT00756912?

Interventions in NCT00756912: E5564.

Is NCT00756912 still recruiting?

NCT00756912 is currently terminated. Last updated 10 July 2014.

Last reviewed 2014-07-10 · How we verify

NCT00756912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Terminated Phase 1 Last updated 10 July 2014

What this trial tests

Phase 1 trial testing E5564 in Leukemia in 30 participants. Terminated before completion.

Timeline

1 September 2008

Primary endpoint
1 November 2008

Quick facts

Lead sponsor	Eisai Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	30
Start date	1 September 2008
Primary completion	1 November 2008
Sites	1 location across United States

Drugs / interventions tested

E5564 — full drug profile →

Conditions studied

Leukemia — all drugs for Leukemia →

Sponsor

Eisai Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Leukemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and assessments will be done daily.
Time frame: Performed daily through Day 28, with follow-up every other week to Day 100 and at 1 year post-transplant.

Sponsor's own description

This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone marrow or blood of another person.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
Barochia A, Solomon S, Cui X, Natanson C, et al · · 2011 · cited 141× · PMID 21323610 · DOI 10.1517/17425255.2011.558190
Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.
Farooq M, Batool M, Kim MS, Choi S. · · 2021 · cited 70× · PMID 34671606 · DOI 10.3389/fcell.2021.756315
Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?
Nunes KP, de Oliveira AA, Mowry FE, Biancardi VC. · · 2019 · cited 46× · PMID 29981161 · DOI 10.1111/bph.14438
Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy.
Lin H, Xiong W, Fu L, Yi J, et al · · 2025 · cited 17× · PMID 40877572 · DOI 10.1186/s43556-025-00305-3

Verify or expand the search:

Other recruiting trials for Leukemia

Currently open trials in the same condition.

NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting

Other Eisai Inc. trials

Trials by the same sponsor.

NCT07493265 — A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy · Phase 2 · not yet recruiting
NCT07308236 — A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants · Phase 1 · recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06744673 — A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control P · active not recruiting
NCT06602258 — A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00756912 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Inc.
Last refreshed: 10 July 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00756912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing